| Literature DB >> 32986231 |
Suchita Hathiramani1, R Pettengell2, H Moir3, A Younis4.
Abstract
PURPOSE: Lymphoma survivors experience persisting needs as a consequence of disease and treatment, which have an impact on quality of life (QoL). There is evidence supporting the use of relaxation and exercise to improve QoL, but there is no agreement on which is more beneficial. This study aims to compare a relaxation intervention versus an exercise intervention to determine which has a greater impact on QoL post-chemotherapy.Entities:
Keywords: Exercise; Lymphoma survivors; Quality of life; Relaxation; Self-management
Year: 2020 PMID: 32986231 PMCID: PMC7520510 DOI: 10.1007/s11764-020-00941-4
Source DB: PubMed Journal: J Cancer Surviv ISSN: 1932-2259 Impact factor: 4.442
Baseline demographics
| Total sample, | Relaxation, | Exercise, | |
|---|---|---|---|
| Age, years (mean | 61 ( | 60.4 ( | 61.5 ( |
| Gender ( | |||
| Male | 17 (37) | 7 (30.4) | 10 (43.5) |
| Female | 29 (63) | 16 (69.6) | 13 (56.5) |
| Marital status ( | |||
| Married/partner | 31 (67) | 14 (61) | 17 (74) |
| Single | 10 (22) | 4 (17) | 6 (26) |
| Widowed | 5(11) | 5 (22) | 0 (0) |
| Ethnicity ( | |||
| Caucasian | 38 (83) | 18 (78.3) | 20 (87.1) |
| Asian | 4 (9) | 3 (13) | 1 (4.3) |
| Afro-Caribbean | 3 (6) | 2 (8.7) | 1 (4.3) |
| Other | 1 (2) | 0 (0) | 1 (4.3) |
| Comorbidities ( | |||
| None | 14 (30.4) | 6 (26.1) | 8 (34.8) |
| 1 | 16 (34.8) | 5 (21.7) | 11 (47.8) |
| 2 | 10 (21.7) | 6 (26.1) | 4 (17.4) |
| 3 or more | 6 (13.1) | 6 (26.1) | 0 (0) |
| ECOG status ( | |||
| 0 | 7 (15) | 4 (17.4) | 3 (13) |
| 1 | 18 (39) | 7 (30.4) | 11 (48) |
| 2 | 21 (46) | 12 (52.2) | 9 (39) |
| Employment ( | |||
| Retired | 21 (45.7) | 11 (47.8) | 10 (43.6) |
| Sick leave | 9 (19.6) | 4 (17.5) | 5 (21.6) |
| Fulltime work | 7 (15.3) | 3 (13) | 4 (17.5) |
| Homemaker | 4 (8.6) | 3 (13) | 1 (4.3) |
| Part-time work | 2 (4.3) | 0 (0) | 2 (8.7) |
| Unemployed | 1 (2.2) | 0 (0) | 1 (4.3) |
| Other | 2 (4.3) | 2 (8.7) | 0 (0) |
Fig. 1Participant flow
EORTC QLQ-C30 domains—means (+ SD) of both groups and between-group comparison, adjusted for baseline. *Indicates significant difference between groups
| Mean 12-week relaxation | Mean 12-week exercise | ||
|---|---|---|---|
| Summary score | 83.69 | 91.07 | 0.029 |
| Physical function | 77.54 | 89.21 | 0.038 |
| Role function | 81.58 | 87.72 | 0.441 |
| Emotional function | 82.02 | 88.60 | 0.267 |
| Cognitive function | 78.07 | 86.84 | 0.367 |
| Social function | 87.72 | 92.10 | 0.444 |
| Fatigue | 35.67 | 17.54 | 0.009 |
| Nausea/vomiting | 4.39 | 0.88 | 0.080 |
| Pain | 14.04 | 5.26 | 0.017 |
| Dyspnoea | 19.30 | 10.56 | 0.093 |
| Insomnia | 17.54 | 5.26 | 0.155 |
| Appetite loss | 10.53 | 8.77 | 0.588 |
| Constipation | 10.53 | 8.77 | 0.588 |
| Diarrhoea | 7.02 | 3.51 | 0.342 |
| Financial problems | 8.77 | 7.41 | 0.911 |
| Global QoL | 74.12 | 80.70 | 0.374 |
Fig. 2Mean QOL over time at baseline, 6 weeks and 12 weeks (dark grey line represents exercise intervention; light grey line represents relaxation intervention)